International Journal of Thyroidology

Table. 1.

Table. 1. Table 1

The summary of clinical characteristics of lenvatinib induced pneumothorax in the literature with our cases

	Age/sex	Cancer type	Surgery	Lung metastasis	Other distant metastases	Cavitations of metastatic lung nodules after lenvatinib	Pneumothorax

							Symptom	Time from lenvatinib initiation	Bilaterality	Lenvatinib dose at the moment of pulmonary event	Treatment	Lenvatinib therapy	Disease response to lenvatinib
Kazzaz et al.⁶⁾	73/M	ATC	TT	+	Mediastinal lymph nodes	+	Mild dyspnea	2 months	Bilateral	NA	Chest tubing and chemical pleurodesis	Temporary cessation and restart with lower dose	Progression during lenvatinib withhold.
Yamazaki et al.⁷⁾	63/M	ATC	None	+	NA	+	None	34 days	Unilateral	20 mg^a	Chest tubing	Maintenance	SD
Lee et al.²⁷⁾	77/M	ATC	None	+	None		Dyspnea	50 days	Bilateral	24 mg^a	Chest tubing and wedge resection	Temporary cessation and restart with lower dose (20 mg)	SD → patient died before 1 month after lenvatinib restarting
Kawanishi et al.³⁰⁾	71/M	HCC	None	+	None	+	Dyspnea, back pain	2 months	Unilateral	12 mg^a	Thoracoscopic wedge resection and chest tubing	Cessation	PD → patients died ten days after discharge
Our case 1 (case 2)	49/F	ATC	None	+	Bone, liver	+	None	353 days	Unilateral	14 mg^a	Supportive care	Temporary cessation and restart at the same dose	PD
Our case 2 (case 3)	80/F	PDTC	TT	+	Bone	+	None	292 days	Unilateral	10 mg^a	Supportive care	Maintenance	SD

ATC: anaplastic thyroid cancer, HCC: hepatocellular carcinoma, NA: not applicable, PD: progressive disease, PDTC: poorly differentiated thyroid cancer, SD: stable disease, TT: total thyroidectomy

^aThe lenvatinib dose at the moment of pulmonary event is the same as the median daily dose before the event.

Int J Thyroidol 2022;15:42-8 https://doi.org/10.11106/ijt.2022.15.1.42